Table S2.
Clinical outcomes in patients with high-risk prostate cancer treated by surgery as a primary treatment compare d to dose-escalated and combined-modality RT.
eRnRrRfeR
(First author, year) n
Median follow up,
months
Clinical staging
Perioperative treatments, %
Salvage
treatments, % PM,
% pN+,
%
BPFS, % DMFS, % CSS, %
ADT RT ADT RT 5-y 10-y 5-y 10-y 5-y 10-y
Shilkrut e t al, 2013 [1]
720 65 ≥cT3/
GS 8-10/
PSA>20
1 HRF 79 80.3±1.9 75.3±3.0 91.4±1.3 88.7±2.2 92.4±1.3 89.6±1.9
238 61 2-3 HRF 88 64.7±3.7 41.4±5.4 77.1±3.3 67.8±4.8 91.1±2.1 75.4±4.3
Van der Ouden, 1998 [2]
56 52
cT 3 G1-2
0 0 - 66 10 53a - 76 61 89 76
27 G3 0a - 52 0 75 65
Ward, 2005 [3] 841 124 cT 3 (GS6-7) 51 16 26 15 56 27 - - 85b 73b 95 90
Zwergel, 2007 [4] 572 25 PSA≥20 47 <1 53 - - 28 25c 52c - - 35 35
Loeb, 2007 [5] 288 88 cT 2b/ GS 8-10 or
PSA>15/ cT 3 18 15 16 28 41 6 - 35 - - - 88
Yossepowitch,
2007-8 [6, 7] 938 66 ≥cT 3/GS 8-10/ PSA>20 - 34e 16e 58d 50d 88 78 97.2 92
Hsu, 2009 [8] 200 71 Unilateral cT 3a 56 34 9 64.5/
53.8f,g
50.8/
51.4f,g
94.2/
97.5b,g
79.9/
90.3b,g
98.5/
98.8g
85.9/
88.3g
Bahler, 2009 [9] 199 73 GS 8-10 (46%) 0 - 47 12 31h - - - 92 82
Spahn, 2010 [10] 372 59 ≥cT 2c/ GS 8-10/
PSA>20 84 - - 57 37 76.6i 56.2i 86.2b 79.5b 91.3 87.2
Ploussard, 2011
[11] 813 63.7 ≥cT 2c/ GS 8-10/
PSA>20 (VHRPC 15%) 22 12 24 11 46 10 74.1 - 96.1 - - -
Boorjian, 2012
[12] 1,238 122 ≥cT 3/ GS 8-10/
PSA>20 34 11 34 20 - - - 92
Briganti, 2012 [13] 1,366 127BFFS/ 187CSS
cT 3/ GS8-10/ PSA 20-
100 (VHRPC 33%) 40 19 - 45 23 69.4j 53.8j - - 96.3 91.1
Joniau, 2012 [14] 51 108 cT 3b-cT 4 65 35 63 22 52.7k 45.8k 78 72.5 91.9 91.9
Yamamoto, 2012
[15] 933 37 cT 3/ GS 8-10/ PSA>20
(VHRPC 44%) 52 0 - 33 12 - 58.5/39.9/
22.7c,l - - - 3249
Roder, 2013 [16] 231 52.8 ≥cT 2c/ GS 8/ PSA>20 9 - - 50 4 - 49j - 81 - 90
Abbreviations: ADT – androgen-deprivation therapy; RT – radiation therapy; BPFS – biochemical failure-free survival; DMFS – distant metastasis-free survival; CSS – cancer-specific survival; PM - positive margins;
HRF – high-risk factor; VHRPC – very high-risk prostate cancer (2-3 HRFs)
a – PSA>0.1 ng/ml on 2 consecutive measurements; b – clinical progression-free survival; c – PSA>0.2 ng/ml; d – PSA>0.2 ng/ml with a subsequent confirmatory increase or a single detectable PSA followed by secondary intervention; e – for BFFS analysis from 605 patients with median follow-up of 46 months; f – PSA≥0.2 ng/ml (any salvage or adjuvant treatment with PSA<0.2 ng/ml are censored); g – <65 years old / ≥65 years old; h – PSA≥0.1 ng/ml; i – PSA≥0.2 ng/ml on two consecutive measurements; j – PSA≥0.2 ng/ml; k – PSA≥0.2 ng/ml or salvage treatment; l – 1/2/3 risk factors.
References:
1. Shilkrut M, Merrick GS, McLaughlin PW et al. T he addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Cancer 2013; 119: 681 -690.
2. van den Ouden D, Hop WC, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998; 160: 1392 -1397.
3. Ward JF, Slezak JM, Blute ML et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent o f prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95: 751-756.
4. Zwergel U, Suttmann H, Schroeder T et al. Outcome of prostate cancer patients with initial PSA> or =20 ng/ml undergoing ra dical prostatectomy. Eur Urol 2007; 52: 1058 -1065.
5. Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 2007; 69:
1170-1175.
6. Yossepowitch O, Eggener SE, Bianco FJ, Jr. et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007; 178: 493-499; discussion 499.
7. Yossepowitch O, Eggener SE, Serio AM et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 2008; 53: 950-959.
8. Hsu CY, Joniau S, Oyen R et al. Correlations between age, Charlson score and outcome in clinical unil ateral T 3a prostate cancer. Asian J Androl 2009; 11: 131 -137.
9. Bahler CD, Foster RS, Bihrle R et al. Radical prostatectomy as initial monotherapy for patients with pathologically confir med high-grade prostate cancer. BJU Int 2010; 105: 1372 -1376.
10. Spahn M, Weiss C, Bader P et al. Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation. Urol Int 2010; 84: 164 -173.
11. Ploussard G, Masson-Lecomte A, Beauval JB et al. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification. Urology 2011; 78: 607 -613.
12. Boorjian SA, Karnes RJ, Viterbo R et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 2011; 117: 2883 -2891.
13. Briganti A, Joniau S, Gontero P et al. Identifying the best candidate for radical prostatectomy among patients with high -risk prostate cancer. Eur Urol 2012; 61: 584 -592.
14. Joniau S, Hsu CY, Gontero P et al. Radical prostatectomy in very high -risk localized prostate cancer: long-term outcomes and outcome predictors. Scand J Urol Nephrol 2012; 46: 164-171.
15. Yamamoto S, Kawakami S, Yonese J et al. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy. Jpn J Clin Oncol 2012; 42: 541 -547.
16. Roder MA, Berg KD, Christensen IJ et al. Radical prostatectomy in clinically localized high -risk prostate cancer: outcome of 231 consecutive patients. Scand J Urol 2013; 47: 19 -25.
